The Asia Pacific biofilms treatment market is expected to reach US$ 512.60million by2027 from US$ 271.40million in 2019. The market is estimated to grow with a CAGR of 8.3% from 2020 to 2027.
The growth of the Asia Pacificbiofilms treatmentmarket is attributed to thegrowing advancements in technology,increasing number of new market players,and rising incidence of diabetic foot ulcers due to surging cases of diabetes. However, antibiotic-drug resistance issuesassociated with biofilms treatment restrain the market growth.
Rapid technological advancements, such as new techniques for improved products and dressings, in wound care management bolsters the biofilms treatmentmarket in China. For instance, in March 2019, scientists from the Institute of Biophysics under the Chinese Academy of Sciences and the University of Science and Technology Beijing created a new method to improve wound dressings by enhancing the dressings blood coagulation and wound healing properties. Developed as a 3D layered nano-fiber sponge, its elasticity increases the sponge and blood cells' interfacial interaction to control bleeding. Moreover, the increasing number of collaborations between international and Chinese players is enhancing product penetration in the country. For instance, in April 2019, ACell (a leading regenerative medicine company) entered into a 10-year product supply and distribution agreement with First Horizon, LLC, and Weihai Jierui Medical Products Co., Ltd. Weihai Jierui is a leading manufacturer and distributor of medical devices in China. Moreover, the increasing number of product approvals and launches in Indiapropels the growth of the market. For instance, in 2018, Axio (India) received FDA approval for its Axiostat, an innovative hemostatic dressing to stop bleeding instantly. It also launched MaxioCel, a next-generation Chitosan-based advanced wound care dressing for faster healing of chronic wounds. International players are also engaging with local companies, which would accelerate themarket growth in the forecast period. For instance, ConvaTec (a developer of innovative medical technologies) conducted a courseon vascular wound assessment and advanced wound management for nurses at its training center in Bangalore. This course is the first-of-its-kind conducted in India, covering various topics.
Countries in Asia Pacific are facing challenges due to an increasing incidence of COVID-19. Currently, India is the third worst-hit country by the COVID-19 outbreak worldwide. Many measures have been implemented to contain the spread, which is resulting in a significant operational disruption in many industries—such as the healthcare industry. Quarantine measures for staff, failures in supply-chain, and reductions in demand are generating serious complications for companies. India strictly implemented lockdown for more than two months. Therefore, various businesses and economies are adversely affected. Asian countries have a maximum number of burn cases. The major focus has been shifted to treat COVID-19 patients instead of planned surgeries and procedures. Also, there is a significant drop in in-patient and out-patient for private hospital chains. Due to the rising number of COVID-19 patients and increasing burden on the healthcare facilities, many clinics/hospitalsare postponing diagnosis and treatment of other health issues or diseases.Countries in Asia Pacificare reporting maximum deaths and laboratory diagnosed positive patients. The COVID-19 pandemic is restraining the Asia Pacific biofilms treatment market, and it is likely to continue in the coming few years.
Based on product,theAsia Pacific biofilms treatment market is segmented intodebridement equipment, gauzes and dressings, grafts and matrices, and others. The gauzes and dressings segment held the largest share of the market in 2019, and the same segment is anticipated to register the highest CAGR in the market during 2020–2027.
The Asia Pacific biofilms treatment market,based on wound,is segmented intotraumatic and surgical wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and others. The traumatic and surgical wounds segment held the market largest share in 2019 and is anticipated to register the highest CAGR in the market during the forecast period.
By enduser, the Asia Pacific biofilms treatment marketis segmented intohospitals, home care settings, and others. The hospitals segment held the largest share of the market in 2019.The same segment is anticipated to register the highest CAGR in the market from 2020 to 2027.
A fewof the primary and secondary sources referred to while preparing the reporton the Asia Pacificbiofilms treatment marketare theInternational Diabetes Federation and World Health Organization.